Portfolio Vice President
Novo Nordisk
Plainsboro, New Jersey
Dr. Otilia Koo, Ph.D., FAAPS, is a Portfolio Vice President at Novo Nordisk. Dr Koo is also the President-elect of AAPS and will become President in 2026-2027. Prior to Novo Nordisk, Dr. Koo was employed by Bristol Myers Squibb and held roles in leading Global Product Development and Supply Program Management, Strategy and Business Operations of BMS Cell Therapy Development and Operations and CMC team leadership. Dr. Koo is an AAPS Fellow and was also a member of the 2020-2025 USP Council of Experts and Chair for the 2020-2025 USP Expert Committee for Complex Excipient Monographs. She was the sole editor for the book, "Pharmaceutical Excipients: Overview, Functionality, and Applications in Research and Industry" published in 2017. Dr. Koo has been the leading guest editor of themed issues in AAPS Journal and AAPS Pharm SciTech. Dr. Koo received her Ph.D. in Pharmaceutics from the University of Illinois at Chicago, and Masters and Bachelor (Pharmacy) Hons from the National University of Singapore.
Disclosure information not submitted.
Tuesday, November 11, 2025
9:30 AM - 10:25 AM CT
Keynote: Pharmaceutical Novel Modalities: Opportunities and Challenges
Tuesday, November 11, 2025
1:30 PM - 2:30 PM CT